Ricevi le ultime notizie sulle azioni Prothena Corp con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di PRTA

Ultime notizie per

Prothena Corp

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Doctor.Healthcare

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

PRTA

RXST

SRPT

Azioni ipervendute con RSI sotto i 30 potrebbero offrire opportunità. Uno sguardo a Prothena, RxSight e Sarepta e ai loro recenti dati.

3 titoli del settore sanitario che si preparano a crescere questo trimestre

Prothena Corporation plc - Ordinary Shares

Prothena Corp PLC

Press Releases

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Prothena Announces Corporate Restructuring

Prothena to Report Second Quarter 2025 Financial Results on August 4

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Absci

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

CytomX Therapeutics

Emergent BioSolutions

Erasca

Gossamer Bio

I-MAB

Inhibrx Biosciences

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Keros Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Monopar Therapeutics

Ocugen

Organogenesis Holdings

RAPT Therapeutics

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Savara

Verastem

XOMA Royalty

JMP Securities

Piper Sandler

Chardan Capital

RBC Capital

HC Wainwright & Co.

Comments

Prothena Corp Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO